Bionical acquires CRO Emas Pharma, extends global footprint

Emas' global operations spread across all parts of the world. (Courtesy of Emas Pharma)

Emas Pharma, a CRO that provides biopharma and medical device services, has been bought by outsourced specialist Bionical and joined the latter’s existing clinical services business.

Founded in 1998 and headquartered in Hitchin, U.K., Emas offers a myriad of services from drug safety, clinical trials, to strategic planning for product development and regulatory support, with footprints in about all key regions worldwide and operations spreading in all continents. That global presence is exactly what Bionical is after.

Bionical's clinical division, which Emas will be joining force with, currently provides the supply of products for clinical trials as well as nurse educator teams, among other public health services. Besides that, Bionical also has a commercial chapter that offers business and commercialization support, and a communications team focused on breakthrough digital approaches in communications between sales reps and healthcare providers.

Infographic Download

Reducing Time to Clinic for Your Biomedical Applications

Gelatin methacryloyl (GelMA)-based biomaterials have been widely used in various biomedical research applications due to their suitable biological properties and tunable physical characteristics. Especially over the past 5 years, GelMA-oriented research and patent applications have been growing exponentially, and many of these research concepts are now being translated towards the clinic. Suitable GelMA biomaterials are therefore indispensable to keep pace with the newest medical innovations.

Download to learn more about the benefits of GelMA in various biomedical applications and how X-Pure® GelMA can help you in your developments.

Detailed financials of the deal was not disclosed, but it’s clear that Emas will continue to operate as a separate business, and current CEO Peter Kennerley will stay on as its head. Both Kennerley and Bionical’s CEO Graham Mclntosh said the M&A is “a perfect synergy” and their services are highly complementary to each other’s.

This is Bionical’s third strategic acquisition in just over a year. In July 2015, it purchased U.S.-based patient education firm McCallan Health, followed by its acquisition in September 2015 of also U.K.-based North 51, a three-division healthcare company that delivers recruitment and contract sales solutions, and creates digital and software products for the healthcare and biopharma industry.

Suggested Articles

CTI Clinical Trial and Consulting Services is buying up fellow CRO Clinart to deepen its reach in the Middle Eastern and Northern African regions.

Viva Biotech is putting down $80 million to buy preclinical contract research organization SYNthesis and boost its outsourcing business.

Popular research network provider TriNetX has seen major interest from The Carlyle Group as it buys up a majority stake in the company.